Wednesday, March 06, 2019 10:59:03 AM
Again, I agree completely.
The chances of a company like CELZ, with all the corruption, blatant daily manipulation, complete lack of transparency and relentless propensity to move lower can ever morph into a bonanza for investors are to me "slim to none".
Can you make money with CELZ? Certainly. I personally expect it will see a nice pop, perhaps to .016 before too long - within a few months in any case. This is why I still hold 1.5 million. I really do not expect much more than that any time soon if ever.
It is painfully obvious from watching the daily action here that the market at large does not believe ANYTHING about this story. Nothing.
The chances of a company like CELZ, with all the corruption, blatant daily manipulation, complete lack of transparency and relentless propensity to move lower can ever morph into a bonanza for investors are to me "slim to none".
Can you make money with CELZ? Certainly. I personally expect it will see a nice pop, perhaps to .016 before too long - within a few months in any case. This is why I still hold 1.5 million. I really do not expect much more than that any time soon if ever.
It is painfully obvious from watching the daily action here that the market at large does not believe ANYTHING about this story. Nothing.
Recent CELZ News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/20/2026 08:45:28 PM
- Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline • GlobeNewswire Inc. • 02/10/2026 02:00:00 PM
- Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain • GlobeNewswire Inc. • 01/13/2026 02:15:00 PM
- Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative • GlobeNewswire Inc. • 01/06/2026 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/31/2025 09:05:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 09:01:58 PM
- Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point • GlobeNewswire Inc. • 12/17/2025 02:15:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/16/2025 09:05:24 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/15/2025 05:15:26 AM
- Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201 • GlobeNewswire Inc. • 12/02/2025 02:15:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/21/2025 09:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 11:12:58 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2025 09:46:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:42 PM
- Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits • GlobeNewswire Inc. • 10/30/2025 01:15:00 PM
- Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds • GlobeNewswire Inc. • 10/29/2025 01:00:00 PM
- Creative Medical Technology Holdings Issues Letter to Shareholders • GlobeNewswire Inc. • 10/27/2025 12:15:00 PM
- Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs • GlobeNewswire Inc. • 10/07/2025 01:15:00 PM
- Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain • GlobeNewswire Inc. • 08/13/2025 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2025 08:45:55 PM
- Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells • GlobeNewswire Inc. • 07/17/2025 01:15:00 PM
